Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Reuben Nichols

Internal Medicine Chicago, IL Medical Doctor

NPI 1598717993 CMS profile 253244

4318 S State St, Chicago, IL 60609

Open in the dashboard

General payments

$5,010

242 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Reuben Nichols of Chicago, IL is reported in the CMS Open Payments database as having received $5,010 across 242 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $41 2
2021 General $1,123 50
2020 General $1,665 87
2019 General $2,181 103

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Reuben Nichols
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Reuben Nichols were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Reuben Nichols Internal Medicine median Middle half National median
2019 $2,181 $159 $48–$570 $163
2020 $1,665 $119 $33–$402 $114
2021 $1,123 $135 $37–$521 $132
2022 $41 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Janssen Pharmaceuticals, Inc $786 29 payments
  2. AstraZeneca Pharmaceuticals LP $764 29 payments
  3. Novo Nordisk Inc $339 19 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $323 14 payments
  5. Amgen Inc. $292 17 payments
  6. Novartis Pharmaceuticals Corporation $288 12 payments
  7. Merck Sharp & Dohme Corporation $264 15 payments
  8. Astellas Pharma US Inc $251 8 payments
  9. Sanofi-Aventis U.S. LLC $241 11 payments
  10. Lilly USA, LLC $222 13 payments
  11. Other $1,241 75 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $4,921 241 payments
  2. Education $89 1 payment
Products named General payments · program years 2019–2022
  1. XARELTO $732 28 payments
  2. FARXIGA $648 22 payments
  3. INVOKANA $311 17 payments
  4. ENTRESTO $288 12 payments
  5. Ozempic $264 14 payments
  6. JANUVIA $264 15 payments
  7. STEGLATRO $204 12 payments
  8. SPIRIVA RESPIMAT $192 8 payments
  9. TRULICITY $185 11 payments
  10. Prolia $168 10 payments
  11. Other $3,390 193 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

242 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record